Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Equity Average (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Equity Average for 15 consecutive years, with $14.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 77.52% to $14.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.9 million, a 77.52% decrease, with the full-year FY2024 number at $68.2 million, down 6.11% from a year prior.
  • Equity Average was $14.9 million for Q3 2025 at Harvard Bioscience, down from $15.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $80.1 million in Q4 2021 to a low of $14.9 million in Q3 2025.
  • A 5-year average of $65.9 million and a median of $73.7 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: grew 4.19% in 2021, then tumbled 77.53% in 2025.
  • Harvard Bioscience's Equity Average stood at $80.1 million in 2021, then fell by 10.04% to $72.1 million in 2022, then grew by 2.19% to $73.7 million in 2023, then fell by 12.69% to $64.3 million in 2024, then tumbled by 76.84% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Equity Average are $14.9 million (Q3 2025), $15.3 million (Q2 2025), and $39.1 million (Q1 2025).